Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kerala Ayurveda Ltd unveiled its 'Vision 2030' plan, targeting Rs. 1,000 Crores in revenue by 2030, powered by 20x growth in the Global E-Product business and 10x growth in Health Services. For H1 FY26, consolidated revenue rose 27% year-on-year to Rs. 74.62 Crores, with Q2 FY26 alone growing 17.7%. India e-commerce surged 52%, US Wellness Centres grew 86%, and the Singapore clinic business was newly integrated. However, profitability took a hit — consolidated EBITDA fell to Rs. 2.04 Crores (down Rs. 5.2 Crores YoY) and PAT stayed negative at -Rs. 4.33 Crores — due to heavy spending on talent, marketing and infrastructure. The company is guiding for Rs. 160 Crores in FY26 revenue (30%+ growth) and has begun engaging investors for a potential fund raise, while also announcing a Bali JV and a premium product launch planned for Q4.
The bold Vision 2030 targets and strong topline growth are encouraging, but ongoing losses and the prospect of a fresh equity raise may dilute existing shareholders and pressure the stock in the near term. Execution on digital expansion and international clinics will be key to justifying the ambitious growth plan.